- Home
- JANX vs NAD Comparison
JANX vs NAD Comparison
Compare JANX & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- NAD
- Stock Information
- Founded
- JANX 2017
- NAD 1999
- Country
- JANX United States
- NAD United States
- Employees
- JANX N/A
- NAD N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- NAD Investment Managers
- Sector
- JANX Health Care
- NAD Finance
- Exchange
- JANX Nasdaq
- NAD Nasdaq
- Market Cap
- JANX 2.2B
- NAD 2.8B
- IPO Year
- JANX 2021
- NAD N/A
- Fundamental
- Price
- JANX $30.34
- NAD $11.85
- Analyst Decision
- JANX Strong Buy
- NAD
- Analyst Count
- JANX 11
- NAD 0
- Target Price
- JANX $83.09
- NAD N/A
- AVG Volume (30 Days)
- JANX 924.6K
- NAD 595.7K
- Earning Date
- JANX 02-27-2025
- NAD 01-01-0001
- Dividend Yield
- JANX N/A
- NAD 4.35%
- EPS Growth
- JANX N/A
- NAD N/A
- EPS
- JANX N/A
- NAD N/A
- Revenue
- JANX $10,588,000.00
- NAD N/A
- Revenue This Year
- JANX N/A
- NAD N/A
- Revenue Next Year
- JANX $191.51
- NAD N/A
- P/E Ratio
- JANX N/A
- NAD N/A
- Revenue Growth
- JANX 30.99
- NAD N/A
- 52 Week Low
- JANX $29.63
- NAD $9.56
- 52 Week High
- JANX $71.71
- NAD $11.64
- Technical
- Relative Strength Index (RSI)
- JANX 32.82
- NAD 49.11
- Support Level
- JANX $31.69
- NAD $11.86
- Resistance Level
- JANX $33.49
- NAD $11.99
- Average True Range (ATR)
- JANX 1.96
- NAD 0.07
- MACD
- JANX -0.09
- NAD -0.01
- Stochastic Oscillator
- JANX 21.27
- NAD 17.65
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.